A Phase 4, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed-dose Combination (FDC) Regimen in Antiretroviral Treatment-experienced Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Not Currently Receiving Any Antiretroviral Therapy.
The purpose of this study is to demonstrate the effectiveness of Symtuza® in a rapid reinitiation model of care in patients with HIV-1 infection and who are treatment-experienced but have been off of antiretroviral therapy (ART) for 12 or more weeks.
Advancing Dignity, Health, and Optimism in Connection With Long Acting Injectables
ADHOC-LA is an observational study of people living with HIV who either are taking, or have taken, a long-acting injectable therapy to manage their HIV. Data from this study will be used to research the ways in which HIV impacts the lives of these patients.
100 项与 The Crofoot Research Center, Inc. 相关的临床结果
0 项与 The Crofoot Research Center, Inc. 相关的专利(医药)
100 项与 The Crofoot Research Center, Inc. 相关的药物交易
100 项与 The Crofoot Research Center, Inc. 相关的转化医学